Regenxbio inc. (RGNX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Revenues
Revenues

17,644

11,768

14,700

7,881

884

40,777

5,306

40,031

132,391

2,040

1,336

6,562

455

1,696

125

2,375

393

4,441

1,140

1,363

644

483

License revenue from related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

1,000

-

150

Reagent sales

-

-

-

-

-

-

-

-

-

-

-

-

-

-

47

107

59

48

61

44

104

23

Grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

23

6

3

14

-151

440

310

Operating Expenses
Cost of revenues

3,409

3,791

2,494

1,927

29

2,843

517

3,872

2,408

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

37,035

33,807

35,692

29,483

25,203

24,329

18,508

21,486

19,550

14,170

12,518

13,917

16,619

16,059

12,560

10,680

6,183

4,812

5,664

4,012

2,791

1,085

General and administrative

14,833

14,450

12,402

13,405

11,558

11,144

9,008

8,318

8,380

4,808

9,444

6,355

6,622

5,742

6,200

6,169

5,479

4,232

2,567

3,397

1,716

1,070

Other operating expenses

67

-

-8

62

-

-11

2

-5

-28

-42

0

-29

-45

-34

2

20

114

-15

1

60

-77

8

Foreign currency transaction losses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25

Total operating expenses

55,344

52,092

50,596

44,753

36,790

38,327

28,031

33,681

30,366

18,638

22,645

21,618

23,377

22,165

18,793

17,327

11,644

9,942

8,487

7,659

4,637

2,184

Loss from operations

-37,700

-40,324

-35,896

-36,872

-35,906

2,450

-22,725

6,350

102,025

-16,598

-21,309

-15,056

-22,922

-20,469

-18,668

-14,952

-11,251

-5,501

-7,347

-6,296

-3,993

-1,701

Other Income (Loss)
Interest income from licensing

848

860

716

762

613

584

109

6,898

1,355

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment income (loss)

-3,186

10,609

431

34,524

2,995

2,893

2,122

1,196

859

601

603

583

929

426

514

515

483

323

15

6

2

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

20

92

Total other income (loss)

-2,338

11,469

1,147

35,286

3,608

3,477

2,231

8,094

2,214

601

603

583

929

426

514

515

483

-

15

6

-

-

Loss before income taxes

-40,038

-28,855

-34,749

-1,586

-32,298

5,927

-20,494

14,444

104,239

-

-20,706

-14,473

-

-

-

-

-

-

-

-

-

-

Income Tax Benefit

-

-2,525

-200

-100

70

-

-1,292

3,850

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-18

-92

Net loss

-40,038

-26,464

-34,584

-1,457

-32,228

4,306

-19,202

10,594

104,239

-15,997

-20,706

-14,473

-21,993

-19,608

-18,154

-14,437

-10,768

-5,178

-7,332

-6,290

-4,011

-1,793

Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net

-785

-158

-108

530

621

154

-103

132

-188

-162

93

-74

-539

-886

332

246

994

-

-26

-

-

-

Total other comprehensive income (loss)

-785

-158

-108

530

621

154

-103

132

-188

-162

93

-74

-539

-886

332

246

994

-

-26

-

-

-

Comprehensive loss

-40,823

-26,622

-34,692

-927

-31,607

4,460

-19,305

10,726

104,051

-16,159

-20,613

-14,547

-22,532

-20,494

-17,822

-14,191

-9,774

-5,871

-7,358

-6,290

-4,011

-1,793

Net loss

-40,038

-26,464

-34,584

-1,457

-32,228

4,306

-19,202

10,594

104,239

-15,997

-20,706

-14,473

-21,993

-19,608

-18,154

-14,437

-10,768

-5,178

-7,332

-6,290

-4,011

-1,793

Net accretion and dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,502

-755

126

Net gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

759

-

Net income (loss) applicable to common stockholders

-

-

-34,584

-1,457

-

4,306

-19,202

10,594

104,239

-15,997

-20,706

-14,473

-21,993

-19,608

-18,154

-14,437

-10,768

-5,178

-7,332

-8,792

-2,497

-1,919

Net income (loss) per share:
Basic

-

-

-0.94

-0.04

-

-0.08

-0.56

0.33

3.30

-0.49

-0.67

-0.47

-0.82

-

-

-

-

-

-

-

-

-

Diluted

-

-

-0.94

-0.04

-

-0.05

-0.56

0.30

3.04

-0.49

-0.67

-0.47

-0.82

-

-

-

-

-

-

-

-

-

Weighted-average common shares outstanding:
Basic

-

-

36,813

36,669

-

36,006

33,988

32,082

31,632

31,237

30,940

30,662

26,673

-

-

-

-

-

-

-

-

-

Diluted

-

-

36,813

36,669

-

43,057

33,988

35,272

34,275

31,237

30,940

30,662

26,673

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share

-1.08

-

-

-

-0.89

-

-

-

-

-

-

-

-

-

-0.69

-0.55

-0.41

3.11

-1.52

-3.24

-0.94

-0.73

Weighted-average basic and diluted common shares outstanding

37,104

-

-

-

36,366

-

-

-

-

-

-

-

-

-

26,469

26,362

26,327

26,526

4,809

2,712

2,645

2,643

License and royalty [Member]
Revenues

-

-

-

-

-

-

-

-

-

-

-

-

455

1,665

65

2,245

328

4,390

65

470

100

-

License [Member]
Costs of revenues

-

-

-

-

-

-

-

-

-

-

-

-

91

333

13

449

66

878

213

294

20

-

Other [Member]
Costs of revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

22

49

30

5

44

16

33

12